The bill has come due for Illumina’s decision to buy Grail now and apologise later. The $30 billion genetic test maker faces a record European Union fine of 432 million euros ($476 million) for closing the $8 billion deal in 2021, ahead of regulatory approval. Grail, which is developing new cancer screening methods, also faces a first-of-its-kind fine for disregarding the authorities, albeit a symbolic 1,000 euros given its status as the target.
for closing the $8 billion deal in 2021, ahead of regulatory approval. Grail, which is developing new cancer screening methods, also faces a first-of-its-kind fine for disregarding the authorities, albeit a symbolic 1,000 euros given its status as the target.
Illumina, which had already provisioned for the thwack, shouldn’t be surprised. The European Commission is not big on companies flouting its processes. Absent the fact that it would have breached its own 10% of revenues cap for fines, the EU would have charged Illumina 570 million euros, according to an EU official. Even so, while the transatlantic merger saga has already seen the departure of Illumina’s chief executive and chairman, Brussels may yet win the battle and lose the war.
The EU’s ongoing complaint about the Illumina-Grail merger may see it order the deal to be unwound, but it could also get blocked by the courts. Separately, Illumina has launched proceedings over whether the EU has the jurisdiction to opine – if it wins, then its new fine could get overturned. U.S.
Deutschland Neuesten Nachrichten, Deutschland Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
Illumina to face record EU antitrust fine for Grail deal, source saysU.S. genetic testing company Illumina will face a record EU antitrust fine on Wednesday for closing its takeover of Grail before it secured approval from EU regulators, a person familiar with the matter said on Tuesday.
Weiterlesen »
Illumina Fined More Than $400 Million in Europe for Closing Grail Deal EarlyBy Kim Mackrael BRUSSELS--The European Union has fined Illumina more than $400 million for proceeding with its acquisition of cancer-test developer Grail...
Weiterlesen »
Illumina hit with record fine for closing Grail deal without EU regulatory approvalThe European Commission last year blocked Illumina's $7.1 billion acquisition of Grail over concerns it would stifle innovation and consumer choice.
Weiterlesen »
Illumina Fined More Than $400 Million in Europe for Closing Grail Deal EarlyThe European Union’s antitrust watchdog fined the company with the maximum allowable amount for wrapping up its acquisition of the cancer-test developer while the agency was still reviewing it.
Weiterlesen »
EU fines U.S. firm Illumina $475 million for jumping gun on buying cancer-screening company GrailThe European Union on Wednesday slapped a $475 million fine on U.S. biotech giant Illumina for buying out cancer-screening company Grail without the approval of the 27-nation bloc’s antitrust watchdog, the latest setback for the deal.
Weiterlesen »
Illumina Fined $476 Million For Acquiring Cancer Test Maker Grail Without EU ApprovalThe record antitrust fine from the EU comes months after the FTC ordered the company to divest its $7.1 billion acquisition of Grail.
Weiterlesen »